Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma Ads (NQ: ASND )

140.95 USD +2.95 (+2.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 524,470
Open 137.80
Bid (Size) 123.00 (2)
Ask (Size) 144.00 (5)
Prev. Close 138.00
Today's Range 135.18 - 141.46
52wk Range 119.11 - 183.98
Shares Outstanding 53,750,386
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 
From GlobeNewswire News Releases
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
From PR Newswire

Performance

YTD
-14.83%
-14.83%
1 Month
+4.70%
+4.70%
3 Month
-2.46%
-2.46%
6 Month
-20.66%
-20.66%
1 Year
-3.14%
-3.14%

More News

Read More
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-To
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences
From GlobeNewswire News Releases
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
Tags ASND Biotech News
From Benzinga
Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.